BELITE BIO INC - AMER

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

03 Nov 2024 16:00:27 By Nasdaq GlobeNewswire

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

14 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

08 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

10 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in Three Upcoming Investor Conferences

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

05 Aug 2024 19:10:54 By Nasdaq GlobeNewswire

Belite Bio to Present at the JonesHealthcare Seaside Summit

08 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

12 Jun 2024 02:55:28 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 21:50:29 By Nasdaq GlobeNewswire

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

06 May 2024 08:15:00 By Nasdaq GlobeNewswire

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

01 May 2024 16:15:00 By Nasdaq GlobeNewswire

Belite Bio Announces $25 Million Registered Direct Offering

25 Apr 2024 19:15:29 By Nasdaq GlobeNewswire